These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 8544674)
21. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. Krumholz HM; Pasternak RC; Weinstein MC; Friesinger GC; Ridker PM; Tosteson AN; Goldman L N Engl J Med; 1992 Jul; 327(1):7-13. PubMed ID: 1598117 [TBL] [Abstract][Full Text] [Related]
23. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries. Cox JL; Lee E; Langer A; Armstrong PW; Naylor CD CMAJ; 1997 Feb; 156(4):497-505. PubMed ID: 9054819 [TBL] [Abstract][Full Text] [Related]
24. Thrombolytic therapy in the elderly. Pharmacoeconomic considerations. Ramanathan K; Ellis CJ; White HD Drugs Aging; 1996 Apr; 8(4):237-44. PubMed ID: 8920173 [TBL] [Abstract][Full Text] [Related]
25. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Wardlaw JM; Warlow CP; Counsell C Lancet; 1997 Aug; 350(9078):607-14. PubMed ID: 9288042 [TBL] [Abstract][Full Text] [Related]
26. [New thrombolytic agents in myocardial infarction]. Charbonnier B; Lang M; Brochier M Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222 [TBL] [Abstract][Full Text] [Related]
27. Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy. Naylor CD; Armstrong PW CMAJ; 1989 Jun; 140(11):1289-99. PubMed ID: 2497946 [TBL] [Abstract][Full Text] [Related]
28. Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. Califf RM; Woodlief LH; Harrell FE; Lee KL; White HD; Guerci A; Barbash GI; Simes RJ; Weaver WD; Simoons ML; Topol EJ Am Heart J; 1997 Jun; 133(6):630-9. PubMed ID: 9200390 [TBL] [Abstract][Full Text] [Related]
29. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents. Woo KS; White HD Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049 [TBL] [Abstract][Full Text] [Related]
30. The impact of economic considerations on clinical decisionmaking: the case of thrombolytic therapy. Brody B; Wray N; Bame S; Ashton C; Petersen N; Harward M Med Care; 1991 Sep; 29(9):899-910. PubMed ID: 1921539 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of thrombolytics: a simplified model. Apikoğlu Rabuş S; Izzettin FV; Sancar M; Rabuş MB; Kirma C; Yakut C Pharm World Sci; 2005 Jun; 27(3):243-8. PubMed ID: 16096895 [TBL] [Abstract][Full Text] [Related]
32. Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA). Tatu-Chiţoiu G; Teodorescu C; Dan M; Guran M; Căpraru P; Istrăţescu O; Tatu-Chiţoiu A; Bumbu A; Chioncel V; Arvanitopol S; Dorobanţu M Rom J Intern Med; 2004; 42(3):557-73. PubMed ID: 16366130 [TBL] [Abstract][Full Text] [Related]
33. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy. Lessler DS; Avins AL Arch Intern Med; 1992 Aug; 152(8):1665-72. PubMed ID: 1497400 [TBL] [Abstract][Full Text] [Related]
34. [A randomized study of streptokinase and recombinant tissue plasminogen activator, with and without heparin, in patients with acute myocardial infarction. The results of GISSI-2/International tPA/SK Mortality Trial]. Steffensen R; Sandøe E Ugeskr Laeger; 1991 Oct; 153(41):2880-3. PubMed ID: 1949301 [TBL] [Abstract][Full Text] [Related]
35. Safe use of thrombolysis in the elderly. Wittry MD; Thornton TA; Chaitman BR Geriatrics; 1989 Nov; 44(11):28-30, 33-6. PubMed ID: 2509296 [TBL] [Abstract][Full Text] [Related]
36. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. Crenshaw BS; Ward SR; Granger CB; Stebbins AL; Topol EJ; Califf RM J Am Coll Cardiol; 1997 Aug; 30(2):406-13. PubMed ID: 9247512 [TBL] [Abstract][Full Text] [Related]
37. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction. Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737 [TBL] [Abstract][Full Text] [Related]
38. ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials. Collins R; Peto R; Parish S; Sleight P Am J Cardiol; 1993 May; 71(12):1127-30. PubMed ID: 8475887 [No Abstract] [Full Text] [Related]
39. Thrombolytic therapy for acute ischaemic stroke. Lane N Lancet; 1997 Nov; 350(9089):1475-6; author reply 1477. PubMed ID: 9371187 [No Abstract] [Full Text] [Related]
40. Controlled trials comparing reteplase with alteplase and streptokinase in patients with acute myocardial infarction. Amsterdam EA Pharmacotherapy; 1996; 16(5 Pt 2):137S-140S. PubMed ID: 8888101 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]